This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Jang, J.-H. Articles by Park, J.-G. Search for Related Content PubMed PubMed Citation Articles by Jang, J.-H. Articles by Park, J.-G.

Novel Transcripts of Fibroblast Growth Factor Receptor 3 Reveal Aberrant Splicing and Activation of Cryptic Splice Sequences in Colorectal Cancer¹

Laboratory of Cell Biology, Cancer Research Institute, Seoul National University College of Medicine, Seoul 110-744, Korea [J-H. J., K-H. S., Y-J. P., J-G. P.]; National Cancer Center, Koyang, Kyunggi 411-351, Korea [J-G. P.]; Department of Developmental and Molecular Biology, Albert Einstein Cancer Center, Albert Einstein College of Medicine, Bronx, New York 10461 [R. J. L.]; and Center for Cancer Biology and Nutrition, Institute of Biosciences and Technology, Texas A&M University System Health Science Center and Department of Biochemistry and Biophysics, Texas A&M University, Houston, Texas 77030-3303 [W. L. M.]

A nested reverse transcription-PCR analysis of FGFR3 from human colorectal carcinomas revealed novel mutant transcripts caused by aberrant splicing and activation of cryptic splice sequences. Two aberrantly spliced transcripts were detected with high frequency in 50% of 36 primary tumors and in 60% of 10 human colorectal cancer cell lines. Most transcripts used normal splice sites but skipped or included exons 8 and 9. Two mutant transcripts arose from cryptic splice donor sites in exon 7 that spliced to exon 10. The predicted translation products would exhibit frameshifts and a premature termination codon in exon 10. We propose that dysregulation of mRNA splicing frequently generates an aberrant FGFR3 transcript that may confer a selectable advantage on clones of cells in colorectal tumorigenesis.

This article has been cited by other articles:

				D. C. Tomlinson, C. G. L'Hote, W. Kennedy, E. Pitt, and M. A. Knowles Alternative Splicing of Fibroblast Growth Factor Receptor 3 Produces a Secreted Isoform That Inhibits Fibroblast Growth Factor-Induced Proliferation and Is Repressed in Urothelial Carcinoma Cell Lines Cancer Res., November 15, 2005; 65(22): 10441 - 10449. [Abstract] [Full Text] [PDF]

				W.-Q. Ding, Z.-J. Cheng, J. McElhiney, S. M. Kuntz, and L. J. Miller Silencing of Secretin Receptor Function by Dimerization with a Misspliced Variant Secretin Receptor in Ductal Pancreatic Adenocarcinoma Cancer Res., September 15, 2002; 62(18): 5223 - 5229. [Abstract] [Full Text] [PDF]

				W.-Q. Ding, S. M. Kuntz, and L. J. Miller A Misspliced Form of the Cholecystokinin-B/Gastrin Receptor in Pancreatic Carcinoma: Role of Reduced Cellular U2AF35 and a Suboptimal 3'-Splicing Site Leading to Retention of the Fourth Intron Cancer Res., February 1, 2002; 62(3): 947 - 952. [Abstract] [Full Text] [PDF]

				J.-H. Jang, K.-H. Shin, and J.-G. Park Mutations in Fibroblast Growth Factor Receptor 2 and Fibroblast Growth Factor Receptor 3 Genes Associated with Human Gastric and Colorectal Cancers Cancer Res., May 1, 2001; 61(9): 3541 - 3543. [Abstract] [Full Text]

				L. L. Knoop and S. J. Baker EWS/FLI Alters 5'-Splice Site Selection J. Biol. Chem., June 15, 2001; 276(25): 22317 - 22322. [Abstract] [Full Text] [PDF]